Market Research Logo

OTC Pharmaceuticals in Europe

OTC Pharmaceuticals in Europe

Summary

OTC Pharmaceuticals in Europe industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings

  • Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the otc pharmaceuticals market in Europe
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the otc pharmaceuticals market in Europe
  • Leading company profiles reveal details of key otc pharmaceuticals market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the Europe otc pharmaceuticals market with five year forecasts
Synopsis

Essential resource for top-line data and analysis covering the Europe otc pharmaceuticals market. Includes market size and segmentation data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
  • What was the size of the Europe otc pharmaceuticals market by value in 2015?
  • What will be the size of the Europe otc pharmaceuticals market in 2020?
  • What factors are affecting the strength of competition in the Europe otc pharmaceuticals market?
  • How has the market performed over the last five years?
  • Who are the top competitors in Europe's otc pharmaceuticals market?
Key Highlights

The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic creams/gels), plasters & bandages (adhesive bandages/plasters, first aid tape, gauze pads/rolled gauze, liquid bandages and other tape or bandage), first aid kits and other (anti-smoking aids, rectal medications, eye/ear drops, sleeping aids, and motion sickness). The market is valued according to retail selling price (RSP) and includes any applicable taxes. Any currency conversions used in the creation of this report have been calculated using constant 2015 annual average exchange rates.

The European OTC pharmaceuticals market generated total revenues of $34,341.4m in 2015, representing a CARC of -4.3% between 2011 and 2015.

Cough and cold preparations registered the highest sales value in the European OTC Pharmaceuticals market in 2015, with total sales of $7,087.9m, equivalent to 20.6% of the market's overall value.

Consumer health products are coming back into fashion among pharmaceutical companies as the looming patent cliff and a backlash against it.


Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market share
Market distribution
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Bayer AG
GlaxoSmithKline Plc
Johnson & Johnson
Novartis AG
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: Europe OTC pharmaceuticals market value: $ million, 2011–15
Table 2: Europe OTC pharmaceuticals market category segmentation: $ million, 2015
Table 3: Europe OTC pharmaceuticals market geography segmentation: $ million, 2015
Table 4: Europe OTC pharmaceuticals market share: % share, by value, 2015
Table 5: Europe OTC pharmaceuticals market distribution: % share, by value, 2015
Table 6: Europe OTC pharmaceuticals market value forecast: $ million, 2015–20
Table 7: Bayer AG: key facts
Table 8: Bayer AG: key financials ($)
Table 9: Bayer AG: key financials (€)
Table 10: Bayer AG: key financial ratios
Table 11: GlaxoSmithKline Plc: key facts
Table 12: GlaxoSmithKline Plc: key financials ($)
Table 13: GlaxoSmithKline Plc: key financials (£)
Table 14: GlaxoSmithKline Plc: key financial ratios
Table 15: Johnson & Johnson: key facts
Table 16: Johnson & Johnson: key financials ($)
Table 17: Johnson & Johnson: key financial ratios
Table 18: Novartis AG: key facts
Table 19: Novartis AG: key financials ($)
Table 20: Novartis AG: key financial ratios
List of Figures
Figure 1: Europe OTC pharmaceuticals market value: $ million, 2011–15
Figure 2: Europe OTC pharmaceuticals market category segmentation: % share, by value, 2015
Figure 3: Europe OTC pharmaceuticals market geography segmentation: % share, by value, 2015
Figure 4: Europe OTC pharmaceuticals market share: % share, by value, 2015
Figure 5: Europe OTC pharmaceuticals market distribution: % share, by value, 2015
Figure 6: Europe OTC pharmaceuticals market value forecast: $ million, 2015–20
Figure 7: Forces driving competition in the OTC pharmaceuticals market in Europe, 2015
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in Europe, 2015
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in Europe, 2015
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in Europe, 2015
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in Europe, 2015
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in Europe, 2015
Figure 13: Bayer AG: revenues & profitability
Figure 14: Bayer AG: assets & liabilities
Figure 15: GlaxoSmithKline Plc: revenues & profitability
Figure 16: GlaxoSmithKline Plc: assets & liabilities
Figure 17: Johnson & Johnson: revenues & profitability
Figure 18: Johnson & Johnson: assets & liabilities
Figure 19: Novartis AG: revenues & profitability
Figure 20: Novartis AG: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report